Study S001019

Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02020616
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: TRIPLE
Status: TERMINATED
Enrollment: 60
Start: 2013-12
Primary completion: 2015-02
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:LY3053102; DRUG:Exenatide ER; DRUG:Placebo; DRUG:Metformin
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I6I-MC-LMRB

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint [Baseline, Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.